Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.65 |
| ▸ | PNP | P00491 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | PDE2A | O00408 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694424 | 1.00 | LMNA (0.65) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL8124562 | 1.00 | LMNA (0.65) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL19242566 | 1.00 | LMNA (0.65) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL13770324 | 0.89 | PDE4D (0.57) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL23585882 | 0.88 | LMNA (0.57) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL25712959 | 0.88 | LMNA (0.59) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL3239663 | 0.88 | LMNA (0.59) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL9601136 | 0.87 | LMNA (0.55) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL7435133 | 0.87 | LMNA (0.58) | LMNAPDE4DPDE3APNPTP53 | |
| SCHEMBL9601706 | 0.86 | LMNA (0.57) | LMNAPDE4DPDE3APNPTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-0355135-A4 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES. | SCRIPPS CLINIC RES (US) | 1990-04-09 | — | — | EP | claimed |
| EP-0355135-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-02-28 | — | — | EP | claimed |
| WO-1989004662-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-06-01 | — | — | WO | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3947408-B1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-1991019726-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | WAKE FOREST UNIVERSITY (US) | 1991-12-26 | — | — | WO | disclosed |
| US-4997926-A | Viricides | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0355135-A4 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES. | SCRIPPS CLINIC RES (US) | 1990-04-09 | — | — | EP | disclosed |
| EP-0355135-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989004662-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885PDE4D 212/4885PDE3A 765/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885PDE4D 212/4885PDE3A 765/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | LMNA 2684/4885PDE4D 105/4885PDE3A 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.